CGRP-mediated trigeminovascular reactivity in migraine patients treated with erenumab
- 27 January 2022
- journal article
- letter
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 93 (8) , 911-912
Abstract
In addition to spontaneous release during migraine, CGRP can be released from trigeminal nerve endings by external stimuli. Application of capsaicin on the forehead releases CGRP via activation of the transient receptor potential cation channel subfamily V member 1 of the trigeminal nerve and thereby increases forehead dermal blood flow (DBF).2 Forearm application of capsaicin also increases DBF and this effect can be inhibited by erenumab, but the dose–response relationship in this model does not seem to be indicative for clinical responses.3Keywords
Funding Information
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek (Spinoza Award 2009 to MDF, VICI grant 09150181910040 to AMvdB)
This publication has 5 references indexed in Scilit:
- E-diary use in clinical headache practice: A prospective observational studyCephalalgia, 2021
- Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b studyThe Lancet, 2018
- CGRP as the target of new migraine therapies — successful translation from bench to clinicNature Reviews Neurology, 2018
- Pharmacokinetic-Pharmacodynamic Relationship of Erenumab (AMG 334) and Capsaicin-Induced Dermal Blood Flow in Healthy and Migraine SubjectsPharmaceutical Research, 2017
- Development of an experimental model to study trigeminal nerve-mediated vasodilation on the human foreheadCephalalgia, 2014